- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02239133
R&D Supporting Pilot Study for the Assessment of the Safety and Effectiveness of the ProVATE (ProTIPI) Vaginal Pessary
Pilot Study for the Evaluation of the ProVATE (ProTIPI) Pessary Designs in the Temporary Management of Pelvic Organ Prolapse (POP) in Women
The study includes five (5) main stages: Screening, Enrollment, Size fitting, Usage and Termination.
Subject screening will be held during visit one (1) and visit two (2) at the clinic.
Initiation and Size fitting:
All eligible subjects will undergo size fitting by a gynecologist / urogynecologist, during visit 2, to find the suitable size for her. The subject will use the ProVATE device of the chosen size at the clinic vicinity for about one (1) hour and for 40-80 hours at her home environment, to confirm that the chosen size is appropriate for the user. Each usage will be followed by a vaginal examination. In case the investigator will determine that the subject should be fitted with a different size of the ProVATE device the subject will repeat this stage with a different device size until the suitable size is confirmed by the investigator.
Usage:
The subject will use the ProVATE device for at least 28 days during a 45 days period, at her home environment, and fill a usage diary. Each device will be used for at least 24 hours. At least one (1) follow-up phone call will be held with the subject per a week. After 14 usage days or following at least two (2) usages (the latest of them) the subject will be scheduled for vaginal examination at the clinic (visit four (4)).
End Of Use At the end of use the subject will return to the clinic (visit five (5)) for a vaginal examination and additional activities.
The following questionnaires will be filled at baseline and end of study: Quality Of Life (QoL) and POP symptoms. Satisfaction and Ease Of Use questionnaires will be filled at the end of use (visit 5) Up to four (4) ProVATE device models will be tested in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Herzliya, Israel
- Site 01
-
Herzliya, Israel
- Site 02
-
ramat HaSharon, Israel
- Site 03
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females aged 21-80 years
- Ability to use both hands and insert a device into the vagina
- Ability to attend the study site as explained by the investigator
- A symptomatic sensation of vaginal prolapse
- The subject has the ability to understand the nature of the study and sign the informed consent
- On examination, the presence of a vaginal wall prolapse of one or more sites
- On examination, POP-Q grade 2 - 4 POP is demonstrated
- A 61-91 mm pessary is well fitted
- A 61-91 mm pessary is well retained
Exclusion Criteria:
- Previous inability to accommodate with tampons or vaginal pessaries
- Subject is currently participating in another clinical study which may directly or indirectly affect the results of this study
- Co-morbid condition(s) or severe systemic disease that could limit the subject 's ability to participate in the study, or impact the scientific integrity of the study
- Subject is pregnant, or suspected to be pregnant or is planning to be pregnant during the course of the study
- Abnormal vaginal bleeding in the past 6 months
- Previous vaginal surgery during the last 3 months
- A severely atrophic vagina
- Existing vaginal or vulvar laceration
- Symptomatic vaginal infection as determined by physical examination and lab results
- Symptomatic urinary tract infection as determined by physical examination and lab results
- Recurrent urinary tract infections
- Abnormal cervical cytology
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ProVATE vaginal pessary
The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse ("POP").
The ProVATE device is similar to other ring pessaries currently on the market.
Its features allow for easy and comfortable insertion and removal by the user herself at her home environment.
The ProVATE device is provided in six (6) different sizes and is intended for prescription use only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Degree of prolapse and POP symptoms following ProVATE device insertion, compared to the degree of prolapse prior to the insertion of the ProVATE device (by vaginal examination)
Time Frame: At day 1 - baseline, and following at least 28 and up to 45 days of using the ProVATE vaginal pessary
|
At day 1 - baseline, and following at least 28 and up to 45 days of using the ProVATE vaginal pessary
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ProVATE PT 103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Organ Prolapse
-
Coloplast A/SCompletedPelvic Organ Prolapse (POP)United States
-
University of CalgaryAlberta Health services; Cook Group IncorporatedCompletedAnterior Pelvic Organ ProlapseCanada
-
University of British ColumbiaCompletedPelvic Organ Prolapse, Patient EducationCanada
-
Unity Health TorontoUnknownVoiding Dysfunction After Pelvic Organ Prolapse SurgeryCanada
-
University of MelbourneCompletedVaginal Hysterectomy | Pelvic Organ Prolapse Vaginal SurgeryAustralia
-
Nykøbing Falster County HospitalZealand University Hospital; University Hospital, Gentofte, Copenhagen; Copenhagen...UnknownBenign Hysterectomy | Postoperative Pelvic Organ Prolapse | Suspension
-
Mackay Medical CollegeRecruitingPelvic Organ Prolapse | Stage III and IV High Grade Pelvic Organ ProlapseTaiwan
-
Peking Union Medical College HospitalUnknown
-
Gaziosmanpasa Research and Education HospitalRecruitingPatients With Pelvic Organ Prolapse | Pectopexy | Lateral Suspension | Pop-q | Pisq-12Turkey
-
Charles University, Czech RepublicUnknownPelvic Organ Prolapse RecurrenceCzech Republic
Clinical Trials on ProVATE vaginal pessary
-
Meir Medical CenterUnknownCystocele | Uterine Prolapse | Rectocele | Use of Pessary Reduce the Number of Prolapse Recurrence
-
Liv Labs Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Servicio de Salud Metropolitano Sur OrientePontificia Universidad Catolica de ChileUnknownQuality of Life | Pelvic Organ ProlapseChile
-
University Hospital, GhentRecruiting
-
Reia, LLCCompleted
-
Assuta Hospital SystemsCompletedStress Urinary IncontinenceIsrael
-
Chinese University of Hong KongKwong Wah HospitalRecruitingPelvic Organ ProlapseHong Kong
-
Procter and GambleCompletedStress Urinary IncontinenceUnited States
-
Medical University of ViennaCompletedPostpartum Urinary IncontinenceGermany
-
IRCCS San RaffaeleNot yet recruitingPelvic Organ Prolapse | Vaginal ProlapseItaly